Administration of Tyra could reverse the downregulation of tumor antigen presentation caused by MAP3K1 mutation, thus promoting CD8+ T cell–mediated antitumor immunity and enhancing the efficacy of anti–PD-1 immunotherapy in HR+/HER2– breast tumors in vivo. The gene discussed is ERBB2; the disease is neoplasm.